Mar 21, 2025 9:11 am EDT Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Mar 5, 2025 8:00 am EST Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Feb 26, 2025 8:00 am EST Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
Dec 19, 2024 8:00 am EST Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Dec 3, 2024 8:00 am EST Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024
Nov 12, 2024 8:00 am EST Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update